Vitamin D and methylarginines in chronic kidney disease (CKD)

about

Vitamin D and methylarginines in chronic kidney disease (CKD)

Item

http://www.wikidata.org/entity/Q42370194

description

2017 nî lūn-bûn

@nan

2017年の論文

@ja

2017年論文

@yue

2017年論文

@zh-hant

2017年論文

@zh-hk

2017年論文

@zh-mo

2017年論文

@zh-tw

2017年论文

@wuu

2017年论文

@zh

2017年论文

@zh-cn

name

Vitamin D and methylarginines in chronic kidney disease (CKD)

@en

Vitamin D and methylarginines in chronic kidney disease

@nl

type

Item

label

Vitamin D and methylarginines in chronic kidney disease (CKD)

@en

Vitamin D and methylarginines in chronic kidney disease

@nl

prefLabel

Vitamin D and methylarginines in chronic kidney disease (CKD)

@en

Vitamin D and methylarginines in chronic kidney disease

@nl

P1476

Vitamin D and methylarginines in chronic kidney disease (CKD)

@en

P2093

Claudia Torino

http://www.w3.org/2001/XMLSchema#string

Francesca Mallamaci

http://www.w3.org/2001/XMLSchema#string

Giovanni Tripepi

http://www.w3.org/2001/XMLSchema#string

Patrizia Pizzini

http://www.w3.org/2001/XMLSchema#string

Rocco Tripepi

http://www.w3.org/2001/XMLSchema#string

Sebastiano Cutrupi

http://www.w3.org/2001/XMLSchema#string

P2860

A more accurate method to estimate glomerular filtration rate from serum creatinine: a new prediction equation. Modification of Diet in Renal Disease Study Group

Administered paricalcitol dose and survival in hemodialysis patients: a marginal structural model analysis

Vitamin D therapy and cardiac structure and function in patients with chronic kidney disease: the PRIMO randomized controlled trial.

Survival of patients undergoing hemodialysis with paricalcitol or calcitriol therapy.

The pathophysiology of erectile dysfunction related to endothelial dysfunction and mediators of vascular function.

Mechanotransduction of bone cells in vitro: mechanobiology of bone tissue.

Randomized trial assessing the effects of ergocalciferol administration on circulating FGF23.

A bench to bedside view of uremic toxins.

Asymmetric dimethylarginine (ADMA) as a prospective marker of cardiovascular disease and mortality--an update on patient populations with a wide range of cardiovascular risk.

The role of asymmetric and symmetric dimethylarginines in renal disease.

P304

e0185449

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1371/JOURNAL.PONE.0185449

http://www.w3.org/2001/XMLSchema#string

P407

English

P433

http://www.w3.org/2001/XMLSchema#string

P478

http://www.w3.org/2001/XMLSchema#string

P50

Carmine Zoccali

P577

2017-10-04T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

28976989

http://www.w3.org/2001/XMLSchema#string

P921

vitamin D

P932

5627906

http://www.w3.org/2001/XMLSchema#string